Fludarabine Disease Interactions
There are 6 disease interactions with fludarabine.
- Infections
- Hemolytic anemia
- Myelosuppression
- Peripheral neuropathy
- Renal dysfunction
- Transfusion/graft-vs-host disease
Antineoplastics (applies to fludarabine) infections
Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.
Fludarabine (applies to fludarabine) hemolytic anemia
Major Potential Hazard, Moderate plausibility.
Life-threatening and sometimes fatal autoimmune hemolytic anemia has been reported in patients with and without previous history of autoimmune hemolytic anemia or a positive Coombs' test during fludarabine therapy. Risk factors that predispose patients to this complication have not been identified. Patients should be instructed to immediately report signs and symptoms suggesting anemia such as fatigue, weakness, and/or bloody urine. Therapy with fludarabine should be administered cautiously in patients with anemia and those with a history of or a predisposition to hemolytic syndromes. Close clinical monitoring of hematopoietic function for hemolysis and anemia is recommended.
Fludarabine (applies to fludarabine) myelosuppression
Major Potential Hazard, High plausibility. Applicable conditions: Bleeding, Fever, Bone Marrow Depression/Low Blood Counts
Fludarabine can severely suppress bone marrow function. Leukopenia, thrombocytopenia, and anemia have been reported during fludarabine therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Therapy with fludarabine should be administered cautiously in patients with bone marrow suppression. Close clinical monitory of hematopoietic function is recommended.
Fludarabine (applies to fludarabine) peripheral neuropathy
Moderate Potential Hazard, Low plausibility.
Peripheral neuropathy has been reported in patients during fludarabine therapy. Therapy with fludarabine should be administered cautiously in patients with a history of or predisposition to neuropathy.
Fludarabine (applies to fludarabine) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Fludarabine is primarily eliminated by the kidney and it should be administered cautiously in patients with renal insufficiency. Patients with moderate impairment of renal function (creatinine clearance 30 to 70 mL/min/1.73 m2) should have their fludarabine dose reduced by 20% and be monitored closely. Fludarabine is not recommended for patients with severely impaired renal function (creatinine clearance less than 30 mL/min/1.73 m2).
Fludarabine (applies to fludarabine) transfusion/graft-vs-host disease
Moderate Potential Hazard, High plausibility. Applicable conditions: Blood Transfusion
Transfusion- associated graft-versus-host disease has been observed rarely after transfusion of non-irradiated blood in fludarabine treated patients. Consideration should, therefore, be given to the use of irradiated blood products in those patients requiring transfusions while undergoing treatment with fludarabine.
Switch to professional interaction data
Fludarabine drug interactions
There are 329 drug interactions with fludarabine.
More about fludarabine
- fludarabine consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: antimetabolites
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Jaypirca
Jaypirca (pirtobrutinib) is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Kesimpta
Kesimpta (ofatumumab) is used to treat relapsing forms of multiple sclerosis. Includes Kesimpta ...
Doxorubicin
Doxorubicin systemic is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder ...
Cyclophosphamide
Cyclophosphamide systemic is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia ...
Dasatinib
Dasatinib is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (CML) ...
Carboplatin
Carboplatin is used alone or in combination with other medications to treat ovarian cancer. Learn ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.